ACBI-4
Based on 1 Customer Validation
ACBI-4 is a selective GTP-loaded active state of KRAS (KRAS(on)) PROTAC degrader, with Kd values of 141 nM against KRASG12R. ACBI-4 forms a stable ternary complex with VHL, triggering ubiquitination and KRAS degradation via the ubiquitin-proteasome system. ACBI-4 induces antiproliferative effects in KRAS mutant-driven cancer cells. ACBI-4 can be used for the research of KRAS mutant-driven cancer.
(Pink: KRas G12R ligand (HY-162960); Blue: VHL ligand (HY-176917); Black: linker).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.01%
- CAS No.: 3097985-19-5
- 화학식: C50H63N15O4S
- 분자량:970.20
-
보관:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
All PROTACs Isoforms
More
Biological Activity
|
KRas G12R 141 nM (Kd) |
ACBI-4 (0.01-10 μM) potently degrades endogenous KRASG12R in Cal-62 cells with a DC50 of 162 nM and 93% maximal degradation at 18 h, acting via a PROTAC-dependent mechanism involving VHL recruitment and proteasomal degradation[1].
ACBI-4 (0.1 nM-10 μM; 6 day) exerts a dose-dependent antiproliferative effect in KRASG12R-driven Cal-62 cells, with no activity in KRAS-independent A375 cells, demonstrating on-target efficacy[1].
ACBI-4 (0.02-1000 nM; 18 h) degrades all tested oncogenic KRAS mutants in transduced GP5d cells, with notably enhanced degradation of KRASG12R, KRASQ61K, KRASQ61L, and KRASQ61R compared to ACBI3 (HY-157228)[1].
ACBI-4 (0.01-10 μM; 18 h) degrades endogenous KRASG12R, KRASQ61K, KRASQ61L, and KRASG12D in their respective cancer cell lines in a dose-dependent manner[1].
ACBI-4 (0.1-10 μM) degrades HiBiT-tagged KRASG12R in Cal-62 cells at a faster rate than compound 1, with a maximum rate of ~0.3 min−1 at concentrations ≥1 μM[1].
ACBI-4 (1 μM; 6 h) selectively degrades KRAS in Cal-62 cells, with minimal degradation of closely related NRAS and HRAS at therapeutic-relevant concentrations, and modulates levels of MAPK pathway-related proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cal-62 (KRASG12R) cancer cells, KRAS-independent A375 cells
-
Concentration:0.1 nM; 1 nM; 10 nM; 100 nM; 1 μM; 10 μM
-
Incubation Time:6 day
-
Result:Induced a dose-dependent antiproliferative effect in Cal-62 cells.
Showed no antiproliferative activity in KRAS-independent A375 cells, confirming on-target activity.
-
Cell Line:retrovirally transduced GP5d cells (multiple KRAS mutants)
-
Concentration:0.02 nM; 0.15 nM; 0.46 nM; 1.4 nM; 4 nM; 12 nM; 37 nM; 111 nM; 333 nM; 1000 nM
-
Incubation Time:18 h
-
Result:Degraded all tested oncogenic KRAS mutants, including KRASG12R, KRASQ61K, KRASQ61L, KRASQ61R, KRASG12D, KRASG12V, KRASG13D, KRASG13V, KRASQ61E, KRASA146P, KRASA146T, and KRASA146V.
Showed significantly improved degradation of KRASG12R, KRASQ61K, KRASQ61L, and KRASQ61R compared to ACBI3, with only KRASA146P showing similar degradation levels to ACBI3.
-
Cell Line:Calu-6 (KRASQ61K), SW948 (KRASQ61L), KP-2 (KRASG12R), GP5d (KRASG12D)
-
Concentration:0.01 μM; 0.03 μM; 0.1 μM; 0.3 μM; 1 μM; 10 μM
-
Incubation Time:18 h
-
Result:Induced dose-dependent degradation of endogenous KRASQ61K in Calu-6 cells.
Induced dose-dependent degradation of endogenous KRASQ61L in SW948 cells, requiring higher concentrations for maximal effect.
Induced dose-dependent degradation of endogenous KRASG12R in KP-2 cells.
Induced dose-dependent degradation of endogenous KRASG12D in GP5d cells.
Chemical Information
-
CAS No. 3097985-19-5
-
Appearance Solid
-
분자량 970.20
-
화학식 C50H63N15O4S
-
Color White to off-white
-
SMILES
CC([C@H](N1N=NC2=C1CC[C@H](CCCN3C[C@@H](N(CCC3)C4=NC(C5=NOC([C@@]6(C7=C(CCC6)SC(N)=C7C#N)C)=N5)=CC=N4)C)C2)C(N8C[C@@H](C[C@H]8C(NCC9=CC=C%10C(N(N=C%10)C)=C9)=O)O)=O)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
용액&용해도
DMSO : 50 mg/mL (51.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0307 mL | 5.1536 mL | 10.3072 mL | 25.7679 mL |
| 5 mM | 0.2061 mL | 1.0307 mL | 2.0614 mL | 5.1536 mL | |
| 10 mM | 0.1031 mL | 0.5154 mL | 1.0307 mL | 2.5768 mL | |
| 15 mM | 0.0687 mL | 0.3436 mL | 0.6871 mL | 1.7179 mL | |
| 20 mM | 0.0515 mL | 0.2577 mL | 0.5154 mL | 1.2884 mL | |
| 25 mM | 0.0412 mL | 0.2061 mL | 0.4123 mL | 1.0307 mL | |
| 30 mM | 0.0344 mL | 0.1718 mL | 0.3436 mL | 0.8589 mL | |
| 40 mM | 0.0258 mL | 0.1288 mL | 0.2577 mL | 0.6442 mL | |
| 50 mM | 0.0206 mL | 0.1031 mL | 0.2061 mL | 0.5154 mL |
ACBI-4 Related Classifications
HY-176792 Related Classifications
Powered by Bioz